David Zaccardelli Sells 245,784 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 245,784 shares of the stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $4.38, for a total transaction of $1,076,533.92. Following the transaction, the chief executive officer now owns 15,004,920 shares in the company, valued at approximately $65,721,549.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

David Zaccardelli also recently made the following trade(s):

• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $483,797.28.

Verona Pharma Trading Up 0.2 %

Shares of NASDAQ:VRNA opened at $34.93 on Thursday. The business’s 50-day moving average is $29.69 and its 200 day moving average is $21.26. The company has a debt-to-equity ratio of 0.72, a current ratio of 8.61 and a quick ratio of 8.61. Verona Pharma plc has a 1 year low of $11.39 and a 1 year high of $35.62. The firm has a market capitalization of $2.79 billion, a P/E ratio of -45.36 and a beta of 0.44.

Verona Pharma (NASDAQ:VRNA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.53). During the same quarter in the previous year, the business posted ($0.11) EPS. On average, research analysts predict that Verona Pharma plc will post -2.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Verona Pharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Hennion & Walsh Asset Management Inc. lifted its position in Verona Pharma by 71.4% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 67,365 shares of the company’s stock worth $1,084,000 after acquiring an additional 28,071 shares during the period. Matisse Capital acquired a new stake in shares of Verona Pharma during the first quarter worth about $312,000. BNP Paribas Financial Markets boosted its position in Verona Pharma by 1,054.4% in the first quarter. BNP Paribas Financial Markets now owns 23,412 shares of the company’s stock valued at $377,000 after buying an additional 21,384 shares during the last quarter. Capstone Investment Advisors LLC acquired a new position in Verona Pharma in the 1st quarter worth approximately $412,000. Finally, Jennison Associates LLC raised its position in Verona Pharma by 0.5% during the 1st quarter. Jennison Associates LLC now owns 1,593,833 shares of the company’s stock worth $25,645,000 after buying an additional 8,448 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Wells Fargo & Company began coverage on shares of Verona Pharma in a research note on Thursday, October 3rd. They issued an “overweight” rating and a $50.00 price objective for the company. Canaccord Genuity Group upped their price objective on Verona Pharma from $35.00 to $37.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd. Truist Financial raised their price objective on Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. Finally, HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of Verona Pharma in a research report on Tuesday, October 1st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $39.33.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.